Anthony Hirsch, MD
Pediatric Allergy/Immunology · Ojai, CANPI 1316269038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novartis at 25.0% of the total. 2025 is the largest year on record at $741, 8.2 times the $91 reported in 2019. That places this record below the midpoint for pediatric allergy/immunology clinicians in CA, where the typical reported total is $1,660.
Across 79 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$416
- Regeneron Healthcare Solutions, Inc.$377
- Sanofi$309
- AstraZeneca$122
- Genentech USA, Inc.$73
- Lilly USA, LLC$64
- plus $301 from 10 others
What the payments were for
- Food & beverage$1,652100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $416 |
| Regeneron Healthcare Solutions, Inc. | 16 | $377 |
| Sanofi | 18 | $309 |
| AstraZeneca | 6 | $122 |
| Genentech USA, Inc. | 3 | $73 |
| Lilly USA, LLC | 3 | $64 |
| Novo Nordisk | 3 | $54 |
| GSK | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Ionis Pharmaceuticals, Inc. | 2 | $39 |
| Pfizer | 2 | $31 |
| Exact Sciences | 1 | $24 |
| Alk-abello, Inc | 1 | $20 |
| Amgen | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Neurelis, Inc. | 1 | $15 |
How this compares
$1,660 in reported general payments places this provider in the 50th percentile of 48 pediatric allergy/immunology providers in California.
See all pediatric allergy/immunology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $48,453 |
| Montelukast Sodium | 111 | $840 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $488 |
| Famotidine | 25 | $236 |
| Fluticasone Propionate | 18 | $48 |
Paid to pharmacies, not to this prescriber.
Other pediatric allergy/immunology in Ojai
- Manish ButteLos Angeles$357K
- Barbara AriueSan Bernardino$112K
- Peck OngLos Angeles$83K
- Christopher LandonVentura$60K
- Brian GreenbergTarzana$45K
- Alejandro Dorenbaum-KracerPalo Alto$42K
- Maria Garcia-LloretLos Angeles$39K
- Talal ChatilaLos Angeles$30K
- Morna DorseySan Francisco$29K
- Ewald StiehmLos Angeles$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.